InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

REPLIGEN CORP

RGEN Clue Score51
United States Fiscal year ends December CIK 0000730272 Results filed 27 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
Martin D Madaus
8 Aug 2025
Director
Buy indirect
1,800
$112.13
$201.83K
Margaret Pax
17 Mar 2025
Director
Buy
250
$150.69
$37.67K
Anthony Hunt
14 Jun 2024
Chief Executive Officer
Buy
2,000
$124.08
$248.16K
Nicolas Barthelemy
14 Jun 2024
Director
Buy
1,200
$125.45
$150.54K
Martin D Madaus
14 Jun 2024
Director
Buy
700
$125.46
$87.82K
Martin D Madaus
14 Jun 2024
Director
Buy
915
$124.54
$113.95K
Martin D Madaus
8 May 2023
Director
Buy
500
$156.18
$78.09K
Martin D Madaus
5 May 2023
Director
Buy
500
$159.19
$79.60K
Martin D Madaus
4 May 2023
Director
Buy
500
$161.15
$80.58K
Manner Carrie Eglinton
16 Mar 2022
Director
Buy
625
$175.02
$109.39K
Showing 250 of 369 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 354
Amendments (4/A) skipped 15
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 160
Sales at will 170
Transactions with no price 0
Shares from compensation/vesting 3,091,951
Sales filed before the plan box existed 166
History held since 6 Dec 2006